Thubrikar Aortic Valve partners with MAC’s MEDICAL Group and expands the TAVI-1 CE Mark trial of the Optimum TAVI System™
Thubrikar Aortic Valve, Inc. today announced its partnership with MAC’s MEDICAL Group, a distributor of cardiovascular devices in Europe, and MAC’s CEO, Ante Cicin-Sain. As part of the exclusive distribution rights agreement for Europe, Mr. Cicin-Sain, MAC’s MEDICAL Group, and their affiliates will co-participate in financing up to 50 implants toward the CE Mark approval of the Optimum TAVI System™. They will also have the option to invest an additional $2 Million in Thubrikar Aortic Valve (the “Company”).
Mr. Cicin-Sain has already funded 3 recent implants in Poland by investing in the Company, joining several heart specialists, Labcor Laboratorios of Brazil; affiliates of China Cardiovascular Research Foundation; and multiple angel groups and individual investors. These 3 implants further demonstrate consistency in the ease of valve delivery as well as the performance of Optimum TAV. MAC’s MEDICAL Group will expand the Optimum TAVI System CE Mark trial to Croatia, Serbia, and other countries.
Dr. Mano Thubrikar, the Company’s Founder and President, stated, “We are very excited to partner with MAC’s MEDICAL Group for expanding and supporting the completion of our CE Mark Trial, and for their vast experience with European marketing and sales of implantable cardiovascular devices.”
